CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent

Jonathan M. Hernandez, Sarah M. Cowgill, Sam Al-Saadi, Amy Collins, Sharona B. Ross, Jennifer Cooper, Desireé Villadolid, Emmanuel Zervos, Alexander Rosemurgy

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Introduction: This study was undertaken to correlate serum CA 19-9 levels and CA 19-9 velocity with disease-free and overall survival after pancreatectomy for adenocarcinoma. Methods: From 1997 to 2002, 96 patients underwent pancreatectomy without adjuvant chemotherapy as the control arm of a large randomized prospective adjuvant therapy trial. After resection, CA 19-9 levels were drawn at baseline, 4 weeks, and 12-week intervals thereafter. CA 19-9 velocity denotes rate of change in CA 19-9 levels over a 4-week period. Postoperative baseline CA 19-9 levels and CA 19-9 velocity were correlated with disease-free and overall survival. Data are presented as median (mean±SD). Results: Disease-free survival was 7 months (14±13.7), and overall survival was 12 months (19±14.3) with 24 (25%) patients alive at 41 months (39±7.8). Baseline CA 19-9 levels and CA 19-9 velocity predicted disease-free (p<0.01) and overall survival (p<0.01). CA 19-9 velocity was a better predictor of overall survival than baseline CA 19-9 (p<0.001). CA 19-9 velocity at disease progression was 131 U/ml/4-weeks (1,684±4,474.8) vs. 1 U/ml/4-weeks (1±3.8) at 22 months for patients without disease progression (p<0.001). Conclusions: CA 19-9 velocity predicts imminent disease progression after resection of pancreatic adenocarcinoma and is a better predictor of overall survival than baseline CA 19-9 levels. CA 19-9 velocity is a reliable and relatively inexpensive means of monitoring patients after resection of pancreatic cancer and should be considered in all patients enrolled in clinical trials as well as patients receiving adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)349-353
Number of pages5
JournalJournal of Gastrointestinal Surgery
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

Pancreatectomy
Disease-Free Survival
Survival
Disease Progression
Adenocarcinoma
Physiologic Monitoring
Adjuvant Chemotherapy
Pancreatic Neoplasms
Clinical Trials
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Surgery
  • Gastroenterology

Cite this

Hernandez, Jonathan M. ; Cowgill, Sarah M. ; Al-Saadi, Sam ; Collins, Amy ; Ross, Sharona B. ; Cooper, Jennifer ; Villadolid, Desireé ; Zervos, Emmanuel ; Rosemurgy, Alexander. / CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. In: Journal of Gastrointestinal Surgery. 2009 ; Vol. 13, No. 2. pp. 349-353.
@article{72599153e1fc41e0935cde00f2ad181b,
title = "CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent",
abstract = "Introduction: This study was undertaken to correlate serum CA 19-9 levels and CA 19-9 velocity with disease-free and overall survival after pancreatectomy for adenocarcinoma. Methods: From 1997 to 2002, 96 patients underwent pancreatectomy without adjuvant chemotherapy as the control arm of a large randomized prospective adjuvant therapy trial. After resection, CA 19-9 levels were drawn at baseline, 4 weeks, and 12-week intervals thereafter. CA 19-9 velocity denotes rate of change in CA 19-9 levels over a 4-week period. Postoperative baseline CA 19-9 levels and CA 19-9 velocity were correlated with disease-free and overall survival. Data are presented as median (mean±SD). Results: Disease-free survival was 7 months (14±13.7), and overall survival was 12 months (19±14.3) with 24 (25{\%}) patients alive at 41 months (39±7.8). Baseline CA 19-9 levels and CA 19-9 velocity predicted disease-free (p<0.01) and overall survival (p<0.01). CA 19-9 velocity was a better predictor of overall survival than baseline CA 19-9 (p<0.001). CA 19-9 velocity at disease progression was 131 U/ml/4-weeks (1,684±4,474.8) vs. 1 U/ml/4-weeks (1±3.8) at 22 months for patients without disease progression (p<0.001). Conclusions: CA 19-9 velocity predicts imminent disease progression after resection of pancreatic adenocarcinoma and is a better predictor of overall survival than baseline CA 19-9 levels. CA 19-9 velocity is a reliable and relatively inexpensive means of monitoring patients after resection of pancreatic cancer and should be considered in all patients enrolled in clinical trials as well as patients receiving adjuvant therapy.",
author = "Hernandez, {Jonathan M.} and Cowgill, {Sarah M.} and Sam Al-Saadi and Amy Collins and Ross, {Sharona B.} and Jennifer Cooper and Desire{\'e} Villadolid and Emmanuel Zervos and Alexander Rosemurgy",
year = "2009",
month = "2",
day = "1",
doi = "10.1007/s11605-008-0696-3",
language = "English (US)",
volume = "13",
pages = "349--353",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "2",

}

Hernandez, JM, Cowgill, SM, Al-Saadi, S, Collins, A, Ross, SB, Cooper, J, Villadolid, D, Zervos, E & Rosemurgy, A 2009, 'CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent', Journal of Gastrointestinal Surgery, vol. 13, no. 2, pp. 349-353. https://doi.org/10.1007/s11605-008-0696-3

CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. / Hernandez, Jonathan M.; Cowgill, Sarah M.; Al-Saadi, Sam; Collins, Amy; Ross, Sharona B.; Cooper, Jennifer; Villadolid, Desireé; Zervos, Emmanuel; Rosemurgy, Alexander.

In: Journal of Gastrointestinal Surgery, Vol. 13, No. 2, 01.02.2009, p. 349-353.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent

AU - Hernandez, Jonathan M.

AU - Cowgill, Sarah M.

AU - Al-Saadi, Sam

AU - Collins, Amy

AU - Ross, Sharona B.

AU - Cooper, Jennifer

AU - Villadolid, Desireé

AU - Zervos, Emmanuel

AU - Rosemurgy, Alexander

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Introduction: This study was undertaken to correlate serum CA 19-9 levels and CA 19-9 velocity with disease-free and overall survival after pancreatectomy for adenocarcinoma. Methods: From 1997 to 2002, 96 patients underwent pancreatectomy without adjuvant chemotherapy as the control arm of a large randomized prospective adjuvant therapy trial. After resection, CA 19-9 levels were drawn at baseline, 4 weeks, and 12-week intervals thereafter. CA 19-9 velocity denotes rate of change in CA 19-9 levels over a 4-week period. Postoperative baseline CA 19-9 levels and CA 19-9 velocity were correlated with disease-free and overall survival. Data are presented as median (mean±SD). Results: Disease-free survival was 7 months (14±13.7), and overall survival was 12 months (19±14.3) with 24 (25%) patients alive at 41 months (39±7.8). Baseline CA 19-9 levels and CA 19-9 velocity predicted disease-free (p<0.01) and overall survival (p<0.01). CA 19-9 velocity was a better predictor of overall survival than baseline CA 19-9 (p<0.001). CA 19-9 velocity at disease progression was 131 U/ml/4-weeks (1,684±4,474.8) vs. 1 U/ml/4-weeks (1±3.8) at 22 months for patients without disease progression (p<0.001). Conclusions: CA 19-9 velocity predicts imminent disease progression after resection of pancreatic adenocarcinoma and is a better predictor of overall survival than baseline CA 19-9 levels. CA 19-9 velocity is a reliable and relatively inexpensive means of monitoring patients after resection of pancreatic cancer and should be considered in all patients enrolled in clinical trials as well as patients receiving adjuvant therapy.

AB - Introduction: This study was undertaken to correlate serum CA 19-9 levels and CA 19-9 velocity with disease-free and overall survival after pancreatectomy for adenocarcinoma. Methods: From 1997 to 2002, 96 patients underwent pancreatectomy without adjuvant chemotherapy as the control arm of a large randomized prospective adjuvant therapy trial. After resection, CA 19-9 levels were drawn at baseline, 4 weeks, and 12-week intervals thereafter. CA 19-9 velocity denotes rate of change in CA 19-9 levels over a 4-week period. Postoperative baseline CA 19-9 levels and CA 19-9 velocity were correlated with disease-free and overall survival. Data are presented as median (mean±SD). Results: Disease-free survival was 7 months (14±13.7), and overall survival was 12 months (19±14.3) with 24 (25%) patients alive at 41 months (39±7.8). Baseline CA 19-9 levels and CA 19-9 velocity predicted disease-free (p<0.01) and overall survival (p<0.01). CA 19-9 velocity was a better predictor of overall survival than baseline CA 19-9 (p<0.001). CA 19-9 velocity at disease progression was 131 U/ml/4-weeks (1,684±4,474.8) vs. 1 U/ml/4-weeks (1±3.8) at 22 months for patients without disease progression (p<0.001). Conclusions: CA 19-9 velocity predicts imminent disease progression after resection of pancreatic adenocarcinoma and is a better predictor of overall survival than baseline CA 19-9 levels. CA 19-9 velocity is a reliable and relatively inexpensive means of monitoring patients after resection of pancreatic cancer and should be considered in all patients enrolled in clinical trials as well as patients receiving adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=59149084072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149084072&partnerID=8YFLogxK

U2 - 10.1007/s11605-008-0696-3

DO - 10.1007/s11605-008-0696-3

M3 - Article

C2 - 18972170

AN - SCOPUS:59149084072

VL - 13

SP - 349

EP - 353

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 2

ER -